Monte Rosa Therapeutics Reports Positive MRT-8102 Phase 1 Study Results
Monte Rosa Therapeutics announced positive results from its Gforce-1 Phase 1 study for MRT-8102, demonstrating normalization of key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) in subjects with elevated cardiovascular disease risk.